Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy - PubMed (original) (raw)
Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy
Toya Ohashi et al. Mol Genet Metab. 2007 Nov.
Abstract
Two recombinant human agalsidase preparations are available for treatment of Fabry disease. We assayed urinary GL-3 (uGL-3) concentration in seronegative and seropositive patients receiving agalsidase beta (1mg/kg). Antibody formation and residual enzyme activity were strongly correlated. Normalization of uGL-3 was achieved more efficiently in seronegatives. But different from previous reports, reduction of uGL-3 level was observed in some seropositive patients.
Similar articles
- Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3.
Vedder AC, Breunig F, Donker-Koopman WE, Mills K, Young E, Winchester B, Ten Berge IJ, Groener JE, Aerts JM, Wanner C, Hollak CE. Vedder AC, et al. Mol Genet Metab. 2008 Jul;94(3):319-25. doi: 10.1016/j.ymgme.2008.03.003. Epub 2008 Apr 18. Mol Genet Metab. 2008. PMID: 18424138 Clinical Trial. - Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.
Ramaswami U, Bichet DG, Clarke LA, Dostalova G, Fainboim A, Fellgiebel A, Forcelini CM, An Haack K, Hopkin RJ, Mauer M, Najafian B, Scott CR, Shankar SP, Thurberg BL, Tøndel C, Tylki-Szymanska A, Bénichou B, Wijburg FA. Ramaswami U, et al. Mol Genet Metab. 2019 May;127(1):86-94. doi: 10.1016/j.ymgme.2019.03.010. Epub 2019 Apr 3. Mol Genet Metab. 2019. PMID: 30987917 Clinical Trial. - A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease.
Bénichou B, Goyal S, Sung C, Norfleet AM, O'Brien F. Bénichou B, et al. Mol Genet Metab. 2009 Jan;96(1):4-12. doi: 10.1016/j.ymgme.2008.10.004. Epub 2008 Nov 20. Mol Genet Metab. 2009. PMID: 19022694 Clinical Trial. - Agalsidase Beta: a review of its use in the management of Fabry disease.
Keating GM, Simpson D. Keating GM, et al. Drugs. 2007;67(3):435-55. doi: 10.2165/00003495-200767030-00007. Drugs. 2007. PMID: 17335299 Review. - Spotlight on agalsidase beta in Fabry disease.
Keating GM, Simpson D. Keating GM, et al. BioDrugs. 2007;21(4):269-71. doi: 10.2165/00063030-200721040-00007. BioDrugs. 2007. PMID: 17628124 Review.
Cited by
- Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies.
Tesmoingt C, Lidove O, Reberga A, Thetis M, Ackaert C, Nicaise P, Arnaud P, Papo T. Tesmoingt C, et al. Br J Clin Pharmacol. 2009 Nov;68(5):765-9. doi: 10.1111/j.1365-2125.2009.03501.x. Br J Clin Pharmacol. 2009. PMID: 19917001 Free PMC article. - Fabry nephropathy: 5 years of enzyme replacement therapy-a short review.
Barbey F, Lidove O, Schwarting A. Barbey F, et al. NDT Plus. 2008 Feb;1(1):11-19. doi: 10.1093/ndtplus/sfm022. Epub 2007 Dec 19. NDT Plus. 2008. PMID: 30792776 Free PMC article. No abstract available. - Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes.
Kitagawa T, Suzuki K, Ishige N, Ohashi T, Kobayashi M, Eto Y, Tanaka A, Odaka H, Owada M. Kitagawa T, et al. Pediatr Nephrol. 2008 Sep;23(9):1461-71. doi: 10.1007/s00467-008-0846-6. Epub 2008 Jun 6. Pediatr Nephrol. 2008. PMID: 18535844 - Administration of anti-CD3 antibodies modulates the immune response to an infusion of α-glucosidase in mice.
Ohashi T, Iizuka S, Shimada Y, Higuchi T, Eto Y, Ida H, Kobayashi H. Ohashi T, et al. Mol Ther. 2012 Oct;20(10):1924-31. doi: 10.1038/mt.2012.133. Epub 2012 Aug 7. Mol Ther. 2012. PMID: 22871665 Free PMC article. - Fabry disease, enzyme replacement therapy and the significance of antibody responses.
Deegan PB. Deegan PB. J Inherit Metab Dis. 2012 Mar;35(2):227-43. doi: 10.1007/s10545-011-9400-y. Epub 2011 Oct 25. J Inherit Metab Dis. 2012. PMID: 22037707 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources